pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 5·1 min read
save

HHS Office of Human Research Protections faces staff shortages, jeopardizing participant safety oversight

Jun 5, 2026·read at STAT ↗RegulatoryNegative

In 2021 the Office of Human Research Protections (OHRP) received a report of a participant suicide during a depression and mobility study at the New York State Psychiatric Institute. The incident prompted OHRP to launch a deep investigation into the study and the institute's oversight processes.

The probe uncovered widespread problems with the institute's ethics board reviews, leading OHRP staff to devote the majority of their time-estimated at 60‑70%-to the case. The findings suggested systemic issues beyond the single trial.

The Food and Drug Administration and the National Institutes of Health became involved, and OHRP placed a hold on all HHS‑funded clinical research at the institute. Shortly after, NIH suspended all grants for human‑subject research there, actions that are rarely taken in biomedical research oversight.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Tiny HHS office tasked with protecting research participants’ safety is running on fumes”

read at STAT ↗
4,388 words · retrieved Jun 5
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
National Institutes of Health5Duke UniversityFATE THERAPEUTICS INCHOOKIPA Pharma Inc.LEADINGUltragenyx Pharmaceutical Inc.University of Pennsylvania
topics
AdCom3Major Depression2ApprovalPsychiatry & CNSRare DiseaseVaccines

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Apr 29In first meeting, federal autism committee focuses on ‘profound autism’STAT
  • 1d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • 2d agoCompass Pathways CEO: Psychedelics company will ‘go slow before we go fast’STAT
  • Sep 25Federal judge rolls back landmark disability protectionsSTAT